KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
KRAS is a small GTPase that is among the most commonly mutated oncogenes in cancer. Here, we discuss KRAS biology, therapeutic avenues to target it, and mechanisms of resistance that tumors employ in response to KRAS inhibition. Several strategies are under investigation for inhibiting oncogenic KRA...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI AG
2024-04-01
|
| Серии: | Current Oncology |
| Предметы: | |
| Online-ссылка: | https://www.mdpi.com/1718-7729/31/4/150 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|